- Home
- AIRI vs BLRX Comparison
AIRI vs BLRX Comparison
Compare AIRI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- BLRX
- Stock Information
- Founded
- AIRI 1979
- BLRX 2003
- Country
- AIRI United States
- BLRX Israel
- Employees
- AIRI N/A
- BLRX N/A
- Industry
- AIRI Military/Government/Technical
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- BLRX Health Care
- Exchange
- AIRI Nasdaq
- BLRX Nasdaq
- Market Cap
- AIRI 13.4M
- BLRX 15.3M
- IPO Year
- AIRI N/A
- BLRX 2011
- Fundamental
- Price
- AIRI $3.38
- BLRX $4.45
- Analyst Decision
- AIRI
- BLRX Strong Buy
- Analyst Count
- AIRI 0
- BLRX 2
- Target Price
- AIRI N/A
- BLRX $19.00
- AVG Volume (30 Days)
- AIRI 38.5K
- BLRX 2.1M
- Earning Date
- AIRI 08-13-2025
- BLRX 08-14-2025
- Dividend Yield
- AIRI N/A
- BLRX N/A
- EPS Growth
- AIRI N/A
- BLRX N/A
- EPS
- AIRI N/A
- BLRX N/A
- Revenue
- AIRI $53,182,000.00
- BLRX $22,340,000.00
- Revenue This Year
- AIRI $5.59
- BLRX N/A
- Revenue Next Year
- AIRI $5.00
- BLRX N/A
- P/E Ratio
- AIRI N/A
- BLRX N/A
- Revenue Growth
- AIRI 0.29
- BLRX 91.68
- 52 Week Low
- AIRI $3.00
- BLRX $2.30
- 52 Week High
- AIRI $9.44
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- AIRI 46.11
- BLRX 50.17
- Support Level
- AIRI $3.31
- BLRX $3.79
- Resistance Level
- AIRI $3.72
- BLRX $4.62
- Average True Range (ATR)
- AIRI 0.20
- BLRX 0.56
- MACD
- AIRI -0.01
- BLRX -0.13
- Stochastic Oscillator
- AIRI 14.63
- BLRX 21.79
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.